Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
Seung Min Jung, Seung-Ki Kwok, Ji Hyeon Ju, Yong-Beom Park, Sung-Hwan Park
Korean J Intern Med. 2019;34(3):669-677. Published online 2017 Nov 29 DOI: https://doi.org/10.3904/kjim.2016.374
Citations to this article as recorded by 
Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis
Yoshiya Tanaka, Yusuke Miyazaki, Masafumi Kawanishi, Hironori Yamasaki, Tsutomu Takeuchi
RMD Open.2024; 10(3): e004480. CrossRef
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L Winthrop, Daniel Alet
Annals of the Rheumatic Diseases.2023; 82(1): 107. CrossRef
Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy
Emre Tekgoz, Seda Colak, Kubra G. Yardimci, Orhan Kucuksahin, Muhammet Cinar, Sedat Yilmaz, Timucin Kasifoglu, Cemal Bes, Burcu Yagiz, Abdulsamet Erden, Levent Kilic, Nilufer A. Kanitez, Ali I. Ertenli, Belkis N. Coskun, Elif D. Ediboglu, Ridvan Mercan, S
JCR: Journal of Clinical Rheumatology.2022; 28(2): e318. CrossRef
Potential Cancer Risk in Patients with Rheumatoid Arthritis: A Longitudinal Korean Population-Based Analysis
Hyo Geun Choi, Ho Suk Kang, Hyun Lim, Joo-Hee Kim, Ji Hee Kim, Seong-Jin Cho, Eun Sook Nam, Kyueng-Whan Min, Ha Young Park, Nan Young Kim, Mi Jung Kwon
Journal of Personalized Medicine.2022; 12(6): 965. CrossRef
The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study
Boyoon Choi, Hyun Jin Park, Yun-Kyoung Song, Yoon-Jeong Oh, In-Wha Kim, Jung Mi Oh
Arthritis Research & Therapy.2022;[Epub] CrossRef
Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
Hong Ki Min, Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee
International Journal of Molecular Sciences.2022; 23(22): 13913. CrossRef
Clinical context for cancer risk of immunosuppressive agents used in dermatology
Timothy Tyler Daugherty, Robert Andrew Swerlick
Dermatologic Therapy.2021;[Epub] CrossRef
TNF in the era of immune checkpoint inhibitors: friend or foe?
Allen Y. Chen, Jedd D. Wolchok, Anne R. Bass
Nature Reviews Rheumatology.2021; 17(4): 213. CrossRef
Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: Cohort study in A real world setting
Seulggie Choi, Byeongzu Ghang, Seogsong Jeong, Daein Choi, Jeong Seok Lee, Sang Min Park, Eun Young Lee
Seminars in Arthritis and Rheumatism.2021; 51(4): 685. CrossRef
Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
Hyeongyeong Kim, Youngdoe Kim, YoungJa Lee
Rheumatology and Therapy.2021; 8(3): 1393. CrossRef
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
The Korean Journal of Internal Medicine.2020; 35(1): 41. CrossRef
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
Journal of Rheumatic Diseases.2020; 27(1): 4. CrossRef